These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 22930585)
1. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation. Ingargiola M; Dittfeld C; Runge R; Zenker M; Heldt JM; Steinbach J; Cordes N; Baumann M; Kotzerke J; Kunz-Schughart LA Cytometry A; 2012 Oct; 81(10):865-73. PubMed ID: 22930585 [TBL] [Abstract][Full Text] [Related]
2. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks. Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302 [TBL] [Abstract][Full Text] [Related]
3. Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. Hosseinimehr SJ; Orlova A; Tolmachev V Hum Antibodies; 2010; 19(4):107-11. PubMed ID: 21178282 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. Xu H; Baidoo K; Gunn AJ; Boswell CA; Milenic DE; Choyke PL; Brechbiel MW J Med Chem; 2007 Sep; 50(19):4759-65. PubMed ID: 17725340 [TBL] [Abstract][Full Text] [Related]
5. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263 [TBL] [Abstract][Full Text] [Related]
6. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046 [TBL] [Abstract][Full Text] [Related]
7. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay. Ingargiola M; Runge R; Heldt JM; Freudenberg R; Steinbach J; Cordes N; Baumann M; Kotzerke J; Brockhoff G; Kunz-Schughart LA Int J Cancer; 2014 Aug; 135(4):968-80. PubMed ID: 24615356 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo. Bogdanov A; Kang HW; Querol M; Pretorius PH; Yudina A Bioconjug Chem; 2007; 18(4):1123-30. PubMed ID: 17508710 [TBL] [Abstract][Full Text] [Related]
10. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Ray GL; Baidoo KE; Wong KJ; Williams M; Garmestani K; Brechbiel MW; Milenic DE Br J Pharmacol; 2009 Aug; 157(8):1541-8. PubMed ID: 19681874 [TBL] [Abstract][Full Text] [Related]
12. [Labeling of CDTPA-dianhydride-coupled CD45 monoclonal antibody with yttrium-90]. Fu YB; Li GP; Meng FY Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1230-2. PubMed ID: 16939927 [TBL] [Abstract][Full Text] [Related]
13. The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab. Novy Z; Laznickova A; Mandikova J; Barta P; Laznicek M; Trejtnar F J Labelled Comp Radiopharm; 2014 Jun; 57(7):448-52. PubMed ID: 24889367 [TBL] [Abstract][Full Text] [Related]
15. Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment. Chakravarty R; Goel S; Valdovinos HF; Hernandez R; Hong H; Nickles RJ; Cai W Bioconjug Chem; 2014 Dec; 25(12):2197-204. PubMed ID: 25389697 [TBL] [Abstract][Full Text] [Related]
16. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599 [TBL] [Abstract][Full Text] [Related]
17. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nordberg E; Friedman M; Göstring L; Adams GP; Brismar H; Nilsson FY; Ståhl S; Glimelius B; Carlsson J Nucl Med Biol; 2007 Aug; 34(6):609-18. PubMed ID: 17707800 [TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119 [TBL] [Abstract][Full Text] [Related]